79080-31-2

Basic information

• Product Name: 1,5-DIMETHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE
• Synonyms: 1,5-DIMETHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE;1,5-DiMethyl-3-(trifluoroMethyl)pyrazole;4-Bromo-1,5-dimethyl-3-trifluoromethyl-4H-pyrazole
• CAS NO: 79080-31-2
• Molecular Formula: C₆H₇F₃N₂
• Molecular Weight: 164.13
• EINECS: 200-258-5
• Product Categories: Pyrazoles & Triazoles;Pyrazoles & Triazoles
• Mol File: 79080-31-2.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 71°C/9mmHg(lit.)
• Flash Point: 45.634 °C
• Appearance: /
• Density: 1.279 g/cm³
• Vapor Pressure: 865mmHg at 25°C
• Refractive Index: 1.4080-1.4120
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,5-DIMETHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,5-DIMETHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE(79080-31-2)
• EPA Substance Registry System: 1,5-DIMETHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE(79080-31-2)

Safety Data

• Hazard Codes: C
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 1993
• HazardClass: 3
• PackingGroup: III
• Hazardous Substances Data: 79080-31-2(Hazardous Substances Data)

Usage

General Description

1,5-DIMETHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE is a chemical compound with the molecular formula C7H8F3N3. It is a pyrazole derivative, a class of heterocyclic compounds that contain a five-membered ring with two nitrogen atoms. 1,5-DIMETHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE is commonly used as a building block or intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential biological activities, including its ability to act as a GABA(A) receptor modulator, which could make it useful in the development of new drugs for neurological disorders. Additionally, 1,5-DIMETHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE is a highly reactive compound and should be handled with caution in a controlled laboratory setting.

InChI:InChI=1/C4H4F4/c1-3(5)2-4(6,7)8/h2H,1H3/b3-2+

Upstream product

• 367-57-7 1,1,1-Trifluoro-2,4-pentanedione 
• 60-34-4 methylhydrazine 
• 116-11-0 2-Methoxypropene 
• 407-25-0 trifluoroacetic anhydride 
• 10010-93-2 5-methyl-3-trifluoromethyl-1H-pyrazole 
• 74-88-4 methyl iodide 
• 1634-04-4 tert-butyl methyl ether 
• 135351-20-1 1,1,1-trifluoro-4-methoxypent-3-en-2-one 

Downstream Products

• 721402-02-4 4-bromo-1,5-dimethyl-3-(trifluoromethyl)-1H-pyrazole 
• 88398-42-9 1,5-dimethyl-3-(trifluoromethyl)-1H-pyrazole-4-sulfonyl chloride 
• 128694-63-3 1-methyl-3-(trifluoromethyl)pyrazole-5-carboxylic acid 

Relevant articles and documents

Ambident polyfluoroalkyl-substituted pyrazoles in the methylation reactions

The reactivity of polyfluoroalkyl-containing pyrazoles has been estimated using the quantum chemical calculations. A good regioselectivity in the methylation of polyfluoroalkylpyrazoles was reached while varying the reaction conditions. Under basic condit

THERAPEUTIC COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R1, R2, R3 and R4 are as defined in the specification, for use in therapy.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.